Gerhard Bogner

Olaparib plus bevacizumab first-line maintenance in ovarian cancer: final overall survival results from the PAOLA-1/ENGOT-ov25 trial

I. Ray-Coquard, Alexandra Léary, Sandro Pignata et al. · Annals of Oncology · 2023 · 339 citations · Full text

Medicine, Oncology, Pharmacology +15

Decrease in gynecological cancer diagnoses during the COVID-19 pandemic: an Austrian perspective

Irina Tsibulak, Elisabeth Reiser, Gerhard Bogner et al. · International Journal of Gynecological Cancer · 2020 · 178 citations · Full text

Medicine, Gynecology, Oncology +16

Combined Transvaginal B-Mode and Color Doppler Sonography for Differential Diagnosis of Ovarian Tumors: Results of a Multivariate Logistic Regression Analysis

M. Schelling, Michael Braun, Walther Kuhn et al. · Gynecologic Oncology · 2000 · 99 citations

Medicine, Gynecology, Oncology +17

Efficacy of maintenance olaparib plus bevacizumab according to clinical risk in patients with newly diagnosed, advanced ovarian cancer in the phase III PAOLA-1/ENGOT-ov25 trial

Philipp Harter, Marie Ange Mouret-Reynier, Sandro Pignata et al. · Gynecologic Oncology · 2021 · 90 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Trebananib or placebo plus carboplatin and paclitaxel as first-line treatment for advanced ovarian cancer (TRINOVA-3/ENGOT-ov2/GOG-3001): a randomised, double-blind, phase 3 trial

Ignace Vergote, Giovanni Scambia, David M. O’Malley et al. · The Lancet Oncology · 2019 · 86 citations · Full text

Medicine, Gynecology, Oncology +11